Peritoneal effects of intravenous iron sucrose administration in rats

Translational Research

Volumn 149, Issue 6, 2007, Pages 304-309

  Breborowicz, Andrzej ^a   Polubinska, Alicja ^a   Breborowicz, Maciej ^a   Simon, Marek ^a   Wanic Kossowska, Maria ^a   Oreopoulos, Dimitrios G ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ELASTASE; ENDOTOXIN; FERRIC HYDROXIDE SUCROSE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EOSINOPHIL; HOMEOSTASIS; INFLAMMATION; LEUKOCYTE DIFFERENTIAL COUNT; MACROPHAGE; MALE; MEMBRANE PERMEABILITY; NONHUMAN; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RAT; WISTAR RAT;

EID: 34249315417     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2006.11.003     Document Type: Article

References (27)

1. McGonigle R.J.S., Husserl F., Wallin J.D., and Fisher J.W. Hemodialysis and continuous peritoneal dialysis effects on erytropoiesis in renal failure. Kidney Int 25 (1984) 430-436
2. Barany P., Clyne N., Hylander B., Johansson A.C., Simonsen O., Larsson R., et al. Subcutaneous epoetin beta in renal anemia: an open multicenter dose titration study of patients on continuous peritoneal dialysis. Perit Dial Int 15 (1995) 54-60
3. Nissenson A.R., Korbet S., Faber M., Burkart J., Gentile D., Hamburger R., et al. Multicenter trial of erythropoietin in patients on peritoneal dialysis. J Am Soc Nephrol 5 (1995) 1517-1529
4. Breborowicz M., Polubinska A., Tam P., Wu G., and Breborowicz A. Effect of iron sucrose on human peritoneal mesothelial cells. Eur J Clin Invest 33 (2003) 1038-1044
5. Bastani B., and Gulley S. Intraperitoneal iron-dextran as a potential route of iron therapy in CAPD patients. Perit Dial Int 16 (1996) 646-648
6. Mars R.L., Moles K., Pope K., and Hargrove P. Use of bolus intraperitoneal iron dextran in continuous ambulatory peritoneal dialysis or continuous cyclic peritoneal dialysis patients receiving recombinant human erythropoietin. Adv Perit Dial 15 (1999) 60-64
7. Vychytil A., and Haag-Weber M. Iron status and iron supplementation in peritoneal dialysis patients. Kidney Int 55 suppl 69 (1999) S71-S78
8. VIII24-8
9. Lim P.S., Wei Y.H., Yu Y.L., and Kho B. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 14 (1999) 2680-2687
10. Rooyakkers T.M., Stroes E.S.G., Kooistra M.P., van Faassen E.E., Hider R.C., Rabelink T.J., et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Europ J Clin Invest 32 suppl 1 (2002) 9-16
11. Agarwal R., Vasavada N., Sachs N.G., and Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65 (2004) 2279-2289
12. Zager R.A., Johnson A.C., and Hanson S.Y. Parenteral iron therapy exacerbates experimental sepsis. Kidney Int 65 (2004) 2108-2112
13. Soybir N., Soybir G., Lice H., Dolay H., Ozseker A., and Koksov F. The effects of desferrioxamin and vitamin E as supplements to antibiotics in the treatment of peritonitis in rats. J R Coll Surg Edinb 47 (2002) 700-704
14. Lowry O.H., Rosenbrough N.J., and Farr A.L. Protein measurement with the folin phenol reagent. J Biol Chem 193 (1951) 265-275
15. Akatsuka M., Yamamoto Y., Tobetto K., Yasui T., and Ando T. Suppressive effects of hyaluronic acid on elastase release from rat peritoneal leukocytes. J Pharm Pharmacol 45 (1993) 110-114
16. Gillian M.B., Sherman M.P., Griscavage J.M., and Ignarro L.J. A spectrophotometric assay for nitrate using NADPH oxidation by aspergillus nitrate reductase. Anal Biochem 212 (1993) 359-365
17. Prakash S., Walele A., Dimkovic N., Bargman J., Vas S., and Oreopoulos D. Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients. Perit Dial Int 21 (2001) 290-295
18. Buis B., Koomen G.C.M., Imholz A.L.T., Struijk D.G., Reddingius R.E., Arisz L., et al. Effect of electric charge on the transperitoneal transport of plasma proteins during CAPD. Nephrol Dial Transplant 11 (1996) 1113-1120
19. Carter T.B., Garris A.G., and Ullian M.E. Rusty peritoneal dialysis fluid after intravenous administration of iron dextran. Am J Kidney Dis 27 (1996) 147-150
20. Zager R.A. Parenteral iron treatment induces MCP-1 accumulation in plasma, normal kidneys, and in experimental nephropathy. Kidney Int 68 (2005) 1533-1542
21. Sengoelge G., Kletzmayr J., Ferrara I., Perschl A., Horl W.H., and Sunder-Plassmann G. Impairment of transendothelial leukocyte migration by iron complexes. J Am Soc Nephrol 14 (2003) 2639-2644
22. Deicher R., Ziai F., Cohen G., Mullner M., and Horl W.H. High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 64 (2004) 728-736
23. Zager R.A., Johnson A.C.M., Hanson S.Y., and Lund S. Parenteral iron compounds sensitize mice to injury-initiated TNF-α: a production and TNF-α release. Am J Physiol Renal Physiol 288 (2005) F290-F297
24. Lehnen-Beyel I., De Groot H., and Rauen U. Enhancement of iron toxicity in L929 cells by D-glucose: accelerated (re-)reduction. Biochem J 368 (2002) 517-526
25. Otaki Y., Nakanishi T., Hasuike Y., Moriguchi R., Nanami M., Hama Y., et al. Defective regulation of iron transporters leading to iron excess in the polymorphonuclear leukocytes of patients on maintenance hemodialysis. Am J Kidney Dis 43 (2004) 1030-1039
26. Carden D., Xiao F., Moak C., Willis B.H., Robinson-Jackson S., and Alexander S. Neutrophil elastase promotes lung microvascular injury and proteolysis of endothelial cadherins. Am J Physiol 275 (1998) H385-H392
27. Schaller G., Schreiber-Mojdehkar B., Wolzt M., Puttinger H., Mittermayer F., Horl W.H., et al. Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients. Kidney Int 68 (2005) 2814-2822